Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Arvinas, Inc. (NASDAQ:ARVN) have been given an average rating of “Moderate Buy” by the twenty ratings firms that are currently covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $20.92.

ARVN has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. BMO Capital Markets lowered their price target on Arvinas from $20.00 to $10.00 and set an “outperform” rating on the stock in a research report on Monday, May 5th. TD Cowen downgraded Arvinas from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. Oppenheimer downgraded Arvinas from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 11th. Finally, Citigroup lowered their price target on Arvinas from $10.00 to $9.50 and set a “neutral” rating on the stock in a research report on Monday, May 5th.

Arvinas Price Performance

Arvinas stock opened at $6.51 on Monday. The company has a market capitalization of $475.17 million, a price-to-earnings ratio of -2.35 and a beta of 2.21. Arvinas has a one year low of $5.90 and a one year high of $36.20. The company’s fifty day moving average price is $7.48 and its two-hundred day moving average price is $15.24.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Thursday, May 1st. The company reported $1.14 EPS for the quarter, topping the consensus estimate of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. Arvinas’s revenue for the quarter was up 646.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.97) EPS. As a group, sell-side analysts anticipate that Arvinas will post -3.81 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Noah Berkowitz sold 8,658 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the transaction, the insider now directly owns 110,023 shares of the company’s stock, valued at $945,097.57. The trade was a 7.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.73% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. acquired a new position in shares of Arvinas in the 4th quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Arvinas by 965.4% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company’s stock worth $33,000 after acquiring an additional 4,219 shares in the last quarter. CWM LLC boosted its holdings in shares of Arvinas by 2,317.5% in the 1st quarter. CWM LLC now owns 7,615 shares of the company’s stock worth $53,000 after acquiring an additional 7,300 shares in the last quarter. KBC Group NV boosted its holdings in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after acquiring an additional 1,255 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new position in shares of Arvinas in the 1st quarter worth approximately $77,000. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.